TY - JOUR AB - Diffuse large B‑cell lymphoma (DLBCL) is a highly heterogeneous malignant tumor type, and epigenetic modifications such as acetylation or deacetylation serve vital roles in its development. Chidamide, a novel histone deacetylase inhibitor, exerts an anticancer effect against various types of cancer. The present study aimed to evaluate the cellular effect of chidamide on a number of DLBCL cell lines and to investigate its underlying mechanism. The results demonstrated that chidamide induced the death of these cells in a concentration‑(0‑30 µmol/l) and time‑dependent (24‑72 h) manner, as determined using the Cell Counting Kit‑8 cell viability assay. Moreover, chidamide promoted cellular apoptosis, which was identified via flow cytometry and western blot analysis, with an increase in cleaved caspase‑3 expression and a decrease in Bcl‑2 expression. Chidamide treatment also decreased the expression level of STAT3 and its phosphorylation, which was accompanied by the downregulation of a class‑I histone deacetylase (HDAC) inhibitor, chidamide. Collectively, these data suggested that chidamide can be a potent therapeutic agent to treat DLBCL by inducing the apoptotic death of DLBCL cells by inhibiting the HDACs/STAT3/Bcl‑2 pathway. AD - Department of Hematology, Cancer Hospital of Shanxi Province, Taiyuan, Shanxi 030013, P.R. China Department of Biochemistry and Molecular Biology, Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China AU - Zhang,Hongwei AU - Chi,Fenqing AU - Qin,Keru AU - Mu,Xiuli AU - Wang,Lieyang AU - Yang,Bin  AU - Wang,Yanli AU - Bai,Min AU - Li,Zhenhua AU - Su,Liping AU - Yu,Baofeng DA - 2021/05/01 DO - 10.3892/mmr.2021.11947 IS - 5 JO - Mol Med Rep KW - DLBCL chidamide HDAC STAT3 Bcl‑2 apoptosis PY - 2021 SN - 1791-2997 1791-3004 SP - 308 ST - Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway T2 - Molecular Medicine Reports TI - Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway UR - https://doi.org/10.3892/mmr.2021.11947 VL - 23 ER -